Adefovir Dipivoxil for the Treatment of Chronic Hepatitis B
Efficacy and safety in HBeAg+ and HBeAg- compensated liver disease
Efficacy and safety in patients with lamivudine-resistant HBV
No adefovir-associated resistance mutations identified up to 48 weeks